Clinical studies

Completed Phase 1 and Phase 2 studies show good efficacy and safety of BupiZenge®. In Phase 2 it was shown *:

  • that BupiZenge® reduced pain in the mouth by 50% compared to standard treatment (p = 0.0002).
  • in the combined effect variable, pain in the mouth and throat, the pain decreased by 31% (p = 0.0032)
  • few and mild side effects, no serious adverse events

*See under publications, Pain reports 2017

More about our Publications here